Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414921 · ClinicalTrials.gov registry record · Phase 2
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
A Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT00414921: Completed Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by University of Cincinnati.
NCT00414921 is a Phase 2 study of Attention Deficit Hyperactivity Disorder that has completed, run by University of Cincinnati. The registered enrollment target is 30 participants, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00414921, a Phase 2 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of two medications--clonidine and methylphenidate--alone or in combination to treat attention deficit hyperactivity disorder in children ages 4 through 6.
Conditions Studied
Interventions
- OTHER placebo
- DRUG clonidine
- DRUG methylphenidate
Study Locations (3)
New York
- University of Rochester Medical Center, Department of Neurology, 919 Westfall Road, Building C - Rochester
Ohio
- University of Cincinnati, Department of Psychiatry, 231 Albert Sabin Way, M: 0559 - Cincinnati
Pennsylvania
- Western Psychiatric Institute and Clinic, ADD Program, 3811 Ohara Street - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-09 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00414921 record still lists
NCT00414921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00414921 reports a single indexed study location in New York, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00414921 about?
NCT00414921 is a clinical study titled "Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)". The purpose of this study is to evaluate the safety and efficacy of two medications--clonidine and methylphenidate--alone or in combination to treat attention deficit hyperactivity disorder in children ages 4 through 6.
What is the current status of trial NCT00414921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2003-09. Estimated completion is 2007-06.
What conditions does trial NCT00414921 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT00414921?
The interventions under investigation include: placebo (OTHER), clonidine (DRUG), methylphenidate (DRUG).
Who is sponsoring clinical trial NCT00414921?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00414921 being conducted?
This trial has 3 study locations across New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00414921's enrollment target sits among peer trials
30 81st of 102 higher than 14 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Stimulant Medication in College Students With ADHD
RECRUITING · Phase 2
-
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
RECRUITING · Phase 2
-
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
COMPLETED · Phase 2
-
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia